More recently, Foy et al. [15] reported that a combination of HER2-targeting active immunotherapy and anti-CTLA-4 antibody therapy increased survival rates from a metastatic CT26/HER2 tumor cell challenge by improving the CTL magnitude and quality. Here, ERBB2 is linked to neoplasm.